Results 131 to 140 of about 81,176 (259)

Withdrawn: Impact of the RNF123 mutation on osteoclast differentiation in familial ankylosing spondylitis

open access: yesRheumatology &Autoimmunity, EarlyView.
Jin S, Ji X, Zhang L, Shi Y, Zhao D, Wan W. Impact of the RNF123 mutation on osteoclast differentiation in familial ankylosing spondylitis. Rheumatol & Autoimmun. 2023;1‐8. doi:10.1002/rai2.12102 Withdrawal: The above article, first published online 11th September 2024, on Wiley Online Library (wileyonlinelibrary.com), has been withdrawn by agreement ...
wiley   +1 more source

Immunosuppressive Medications and Nonserious Infections in People With Rheumatoid Arthritis: A Prospective Cohort Study

open access: yesACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective People with rheumatoid arthritis (RA) are at increased risk of serious infection, but less is known about nonserious infections. Our prospective cohort study evaluated associations between medications for RA and the risk of nonserious infections.
Michael D. George   +8 more
wiley   +1 more source

Transthoracic Echocardiography findings in patients with Ankylosing Spondylitis in Kurdistan region

open access: yesAdvanced Medical Journal
Background and objectives: Ankylosing spondylitis is a chronic inflammatory disorder that affecting axial and non-axial joints leads to a loss of mobility and function over time.
Elaf Kamal Abdulwahab   +1 more
doaj   +1 more source

Tumor Necrosis Factor Inhibitor Treatment and Persistence Patterns in the Peripregnancy Period in Patients With Inflammatory Autoimmune Diseases

open access: yesACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective Systemic inflammatory conditions affect many women during their reproductive years and tumor necrosis factor inhibitors (TNFi) are one of the most common biologic classes used to help manage disease in this population. Although treatment guidelines now recommend continuing TNFi in pregnancy, studies examining recent real‐world treatment ...
Anna Sheahan   +6 more
wiley   +1 more source

Elevated Serum Proadrenomedullin Levels in Rheumatoid Arthritis Versus Spondyloarthritis: Insights From a Biobank Cohort

open access: yesACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective Proadrenomedullin (pro‐ADM) is a peptide implicated in immunomodulation, with higher levels observed in inflammatory conditions, cardiovascular impairment, and sepsis. Although extensively studied in acute disorders, its potential as a biomarker in inflammatory arthritis remains underexplored.
Nefeli Stavroula Papastathopoulou   +10 more
wiley   +1 more source

Plasma Proteomics Identifies Thousand‐and‐One–Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

open access: yesArthritis &Rheumatology, Volume 78, Issue 5, Page 1045-1061, May 2026.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin   +15 more
wiley   +1 more source

Spondyloarthritis Associated With Collagenous Colitis—Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Collagenous colitis (CC) is a subtype of microscopic colitis characterized by chronic watery diarrhea with normal endoscopic findings. Although often linked to autoimmune diseases, its association with spondyloarthropathy (SpA) is rare and poorly documented.
Charlotte Bouvy   +4 more
wiley   +1 more source

Morphea Induced by Golimumab in a Patient With Ankylosing Spondylitis: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Morphea is a localized autoimmune fibrosing disorder that may paradoxically develop during anti‐TNFα agents in ankylosing spondylitis (AS). We report a second case of morphea associated with long‐term golimumab use in a patient with AS, presenting with indurated plaques and confirmed histopathologically.
Faten Hilwanjee   +3 more
wiley   +1 more source

Targeting of Gut Microbiota by Bioactive Peptides for the Improvement of Metabolic Diseases: A Review

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
Bioactive peptides (BPs) derived from dietary proteins modulate the gut microbiotametabolism axis by reshaping microbial composition and regulating key metabolites, including short‐chain fatty acids. BPs also enhance intestinal barrier integrity and immune homeostasis, thereby reducing inflammation.
Jiao Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy